Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8- methoxypsoralen

Drug Metabolism and Disposition

Volumn 25, Issue 12, 1997, Pages 1407-1415

  Koenigs, Luke L ^b   Peter, Raimund M ^b   Thompson, Stella J ^b   Rettie, Allan E ^b   Trager, William F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN; CYTOCHROME P450; METHOXSALEN; PILOCARPINE; POTASSIUM FERRICYANIDE; REACTIVE OXYGEN METABOLITE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CONCENTRATION RESPONSE; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; CHILD; COUMARINS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; ENZYME ACTIVATION; FEMALE; HUMANS; KINETICS; MALE; METHOXSALEN; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NADP; NADPH-FERRIHEMOPROTEIN REDUCTASE; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TIME FACTORS;

EID: 0031451433     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. R. Pearce, D. Greenway, and A. Parkinson: Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicoumarol, and testosterone oxidation. Arch. Biochem. Biophys. 298, 211-225 (1992).
2. T. Shimada, H. Yamazaki, and F. P. Guengerich: Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 26, 395-403 (1996).
3. D. J. Waxman, D. P. Lapenson, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, and K. Korzekwa: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290, 160-166 (1991).
4. S. Yamano, J. Tatsuno, and F. J. Gonzalez: The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29, 1322-1329 (1990).
5. J. S. Miles, A. W. McLaren, L. M. Forrester, M. J. Glancey, M. A. Lang, and C. R. Wolf: Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem. J. 267, 365-371 (1990).
6. C. Yun, T. Shimada, and F. P. Guengerich: Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. 40, 679-685 (1991).
7. G. Reigh, H. McMahon, M. Ishizaki, T. Ohara, K. Shimane, Y. Esumi, C. Green, C. Tyson, and S. Ninomiya: Cytochrome P450 species involved in the metabolism of quinoline. Carcinogenesis 17, 1989-1996 (1996).
8. M. Nakajima, T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashimi, K. Inque, Y. Funae, N. Shimada, T. Kamataki, and Y. Kuroiwa: Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos. 24, 1212-1217 (1996).
9. M. Nakajima, T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashimi, K. Inque, Y. Funae, N. Shimada, T. Kamataki, and Y. Kuroiwa: Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277, 1010-1015 (1996).
10. S. J. Thompson, L. L. Koenigs, M. Fisher, D. Slone, D. Eaton, and A. E. Rettie: Baculovirus Mediated Expression, Purification, and Catalytic Activity of Human CYP2A6. Toxicologist 36, 22 (Abstr. 109) (1997).
11. X. Ding, D. C. Spink, J. K. Bhama, J. J. Sheng, A. D. N. Vaz, and M. J. Coon: Metabolic activation of 2,6-dichlorobenzonitrile, an olfactory-specific toxicant, by rat, rabbit, and human cytochromes P450. Mol. Pharmacol. 49, 1113-1121 (1996).
12. R. J. Duescher and A. A. Elfarra: Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. Arch. Biochem. Biophys. 311, 342-349 (1994).
13. F. P. Guengerich, T. Shimada, C. Yun, H. Yamazaki, K. D. Raney, R. Thier, B. Coles, and T. M. Harris: Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes. Environ. Health Perspect. 102, 49-53 (1994).
14. L. M. Forrester, C. J. Henderson, M. J. Glancey, D. J. Back, B. K. Park, S. E. Ball, N. R. Kitteringham, A. W. McLaren, J. S. Miles, P. Skett, and C. R. Wolf: Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem. J. 281, 359-368 (1992).
15. H. Yamazaki, M. Mimura, C. Sugahara, and T. Shimada: Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7α- and coumarin 7-hydroxylations. Biochem. Pharmacol. 48, 1524-1527 (1994).
16. T. F. Anderson and J. J. Voorhees: Psoralen photochemotherapy of cutaneous disorders. Annu. Rev. Pharmacol. Toxicol. 20, 235-257 (1980).
17. R. Edelson, C. Berger, F. Gasparro, B. Jegasothy, P. Heald, B. Wintroub, E. Vonderheid, R. Knobler, K. Wolff, G. Plewig, G. McKiernan, I. Christiansen, M. Oster, H. Honigsman, H. Wilford, E. Kokoschka, T. Rehle, M. Perez, G. Stingl, and L. Laroche: Treatment of cutaneous T cell lymphoma by extracorporeal photochemotherapy. N. Engl. J. Med. 316, 297-303 (1987).
18. J. A. Parrish, T. B. Fitzpatrick, L. Tanenbaum, and M. A. Pathak: Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N. Engl. J. Med. 291, 1207-1211 (1974).
19. H. Fouin-Fortunet, M. Tinel, V. Descatoire, P. Letteron, D. Larrey, J. Geneve, and D. Pessayre: Inactivation of cytochrome P-450 by the drug methoxsalen. J. Pharmacol. Exp. Ther. 236, 237-247 (1986).
20. G. Labbe, V. Descatoire, P. Beaune, P. Letteron, D. Larrey, and D. Pessayre: Suicide inactivation of cytochrome P-450 by methoxsalen: evidence for the covalent binding of a reactive intermediate to the protein moiety. J. Pharmacol. Exp. Ther. 250, 1034-1042 (1989).
21. P. Letteron, V. Descatoire, D. Larrey, M. Tinel, J. Geneve, and D. Pessayre: Inactivation and induction of cytochrome P-450 by various psoralen derivatives in rats. J. Pharmacol. Exp. Ther. 238, 685-692 (1986).
22. D. C. Mays, J. B. Hilliard, D. D. Wong, and N. Gerber: Activation of 8-methoxypsoralen by cytochrome P-450. Biochem. Pharmacol. 38, 1647-1655 (1989).
23. D. C. Mays, J. B. Milliard, D. D. Wong, M. A. Chambers, S. S. Park, H. V. Gelboin, and N. Gerber: Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition of drug metabolism and distribution of covalent adducts. J. Pharmacol. Exp. Ther. 254, 720-731 (1990).
24. M. Tinel, J. Belghiti, V. Descatoire, G. Amouyal, P. Letteron, J. Geneve, D. Larrey, and D. Pessayre: Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem. Pharmacol. 36, 951-955 (1987).
25. J. Maenpaa, H. Sigusch, H. Raunio, T. Syngelma, P. Vuorela, H. Vuorela, and O. Pelkonen: Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem. Pharmacol. 45, 1035-1042 (1993).
26. J. Maenpaa, R. Juvonen, H. Raunio, A. Rautio, and O. Pelkonen: Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem. Pharmacol. 48, 1363-1369 (1994).
27. S. Ono, T. Hatanaka, H. Hotta, T. Satoh, F. J. Gonzalez, and M. Tsutsui: Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26, 681-693 (1996).
28. B. G. Lake, M. J. Sauer, F. Esclangon, J. A. Beamond, R. J. Price, and D. G. Walters: Metabolism of coumarin by precision-cut calf liver slices and calf liver microsomes. Xenobiotica 25, 133-141 (1995).
29. P. Salonpaa, J. Hakkola, M. Pasanen, O. Pelkonen, K. Vahakangas, N. Battula, K. Nouso, and H. Raunio: Retrovirus-mediated stable expression of human CYP2A6 in mammalian cells. Eur. J. Pharmacol. 221, 95-102 (1993).
30. 14C-methoxsalen by the dog. Drug Metab. Dispos. 7, 220-225 (1979).
31. D. C. Mays, S. L. Rogers, R. C. Guiler, D. E. Sharp, S. G. Hecht, A. E. Staubus, and N. Gerber: Disposition of 8-methoxypsoralen in the rat: methodology for measurement, dose-dependent pharmacokinetics, tissue distribution and identification of metabolites. J. Pharmacol. Exp. Ther. 236, 364-373 (1986).
32. D. C. Mays, S. G. Hecht, S. E. Unger, C. M. Pacula, J. M. Climie, D. E. Sharp, and N. Gerber: Disposition of 8-methoxypsoralen in the rat: induction of metabolism in vivo and in vitro and identification of urinary metabolites by thermospray mass spectrometry. Drug Metab. Dispos. 15, 318-328 (1987).
33. J. Schmid, A. Prox, A. Reuter, H. Zipp, and F. W. Koss: The metabolism of 8-methoxypsoralen in man. Eur. J. Drug Metab. Pharmacokinet. 5, 81-92 (1980).
34. F. A. de Wolff and T. V. Thomas: Clinical pharmacokinetics of methoxsalen and other psoralens. Clin. Pharmacokinet. 11, 62-75 (1986).
35. U. Busch, J. Schmid, F. W. Koss, H. Zipp, and A. Zimmer: Pharmacokinetics and metabolite-pattern of 8-methoxypsoralen in man following oral administration as compared to the pharmacokinetics in rat and dog. Arch. Dermatol. Res. 262, 255-265 (1978).
36. A. E. Rettie, A. C. Eddy, L. D. Heimark, M. Gibaldi, and W. F. Trager: Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17, 265-270 (1989).
37. R. L. Haining, A. P. Hunter, M. E. Veronese, W. F. Trager, and A. E. Rettie: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 333, 447-457 (1996).
38. A. L. Shen, M. J. Christensen, and C. B. Kaspar: NADPH-cytochrome P-450 oxidoreductase: the role of cysteine 566 in catalysis and cofactor binding. J. Biol. Chem. 266, 19976-19980 (1991).
39. M. Bourdi, W. Chen, R. M. Peter, J. L. Martin, J. T. M. Buters, S. D. Nelson, and L. R. Pohl: Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem. Res. Toxicol. 9, 1159-1166 (1996).
40. L. Wilkinson: "SYSTAT: The System for Statistics." SYSTAT Inc., Evanston, IL, 1987.
41. R. Silverman: "Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology." Vol. 1, CRC Press, Boca Raton, FL, 1988.
42. A. Rettie, K. Korzekwa, K. Kunze, R. Lawrence, A. Eddy, T. Aoyama, H. Gelboin, F. Gonzalez, and W. Trager: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P450 2C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
43. L. C. Weinkers, C. J. Wurden, E. Storch, K. L. Kunze, A. E. Rettie, and W. F. Trager: Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab. Dispos. 24, 610-614 (1996).
44. T. Kornbach: Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods Enzymol. 206, 509-517 (1991).
45. R. Peter, R. Bocker, P. Beaune, M. Iwasaki, F. Guengerich, and C. Yang: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem. Res. Toxicol. 3, 566-573 (1990).
46. T. Kimonen, M. Pasanen, J. Gynther, A. Poso, T. Jarvinen, E. Alhava, and R. O. Juvonen: Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6. Br. J. Pharmacol. 116, 2625-2630 (1995).
47. m. Biochim. Biophys. Acta 242, 519-522 (1971).
48. O. Pelkonen, E. A. Sotaniemi, and J. T. Ahokas: Coumarin 7-hydroxylase activity in human liver microsomes: properties of the enzyme and interspecies comparisons. Br. J. Clin. Pharmacol. 19, 59-66 (1985).
49. J. H. Fentem and J. R. Fry: Metabolism of coumarin by rat, gerbil and human liver microsomes. Xenobiotica 22, 357-367 (1992).
50. C. Liu, X. Zhou, F. J. Gonzalez, and X. Ding: Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6: role in metabolic activation of nasal toxicants. Mol. Pharmacol. 50, 781-788 (1996).
51. K. L. Kunze and W. F. Trager: Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656 (1993).
52. T. D. Podoll: "Defining the Use of Midazolam as a Probe of CYP3A4 Activity: Sensitive Quantitation of the Metabolites and Characterization of Mechanism-Based Inactivation." University of Washington, Ph.D. Thesis (1996).
53. 1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8, 218-225 (1995).
54. T. R. Devereux, K. G. Jones, J. R. Bend, J. R. Fouts, C. N. Statham, and M. R. Boyd: In vitro metabolic activation of the pulmonary toxin. 4-ipomeanol, in nonciliated bronchiolar epithelial (Clara) and alveolar type II cells isolated from rabbit lung. J. Pharmacol. Exp. Ther. 220, 223-227 (1981).
55. D. Thomassen, N. Knebel, J. T. Slattery, R. H. McClanahan, and S. D. Nelson: Reactive intermediates in the oxidation of menthofuran by cytochromes P-450. Chem. Res. Toxicol. 5, 123-130 (1992).